Previous Article | Next Article ![]()
Molecular and Cellular Biology, May 2007, p. 3769-3779, Vol. 27, No. 10
0270-7306/07/$08.00+0 doi:10.1128/MCB.01432-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
,
Centre for Epigenetics and BRIC, University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen, Denmark,1 Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen, Denmark,2 Department of Experimental Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy,3 Institute of Molecular Oncology of the Italian Foundation for Cancer Research, Via Adamello 16, 20139 Milan, Italy4
Received 3 August 2006/ Returned for modification 10 October 2006/ Accepted 22 February 2007
|
|
|---|
|
|
|---|
Embryonic stem (ES) cells isolated from the inner cell mass (ICM) of preimplantation embryos (embryonic day 3.5 [E3.5]) are immortal and pluripotent. Their self-renewal requires leukemia inhibitory factor (LIF)-dependent Stat3 activation as well as the expression of ES cell-specific transcription factors like Nanog and Oct4 (2). ES cells can give rise to all the somatic cells of an organism and can be differentiated in vitro to all cell types. They are therefore attractive as a tool to study the molecular mechanisms that control cell fate decisions during development.
Cell fate decisions start taking place before embryo implantation, and ICM pluripotency is already lost during embryo gastrulation (
E7.5). Cell type specifications occur through the establishment of specific gene expression programs that require epigenetic-dependent transcriptional regulation (2). Epigenetic control of transcription involves modifications of both DNA and histones, and the factors that can "write" and "read" these modifications play a critical role during development (22).
Consistent with this model of development, it has not been possible to establish Ezh2/ ES cell lines in tissue culture (30). In contrast, Eed/ ES cells can be expanded in tissue culture even though the cells lack global levels of H3K27 methylation (26). Eed/ ES cells have an increased expression of differentiation-specific genes, and the cells "tend" to lose pluripotency (4). The discrepancy between the phenotypes of Ezh2/ and Eed/ ES cells suggests that Ezh2 could have independent functions that do not involve H3K27 methylation. In addition, recent reports have shown that both PRC2 and the PRC1 are required to maintain the repression of differentiation-specific genes in mouse and humans ES cells as well as in human embryonic lung fibroblasts (TIG3) (4, 5, 21).
Here we describe the role of Suz12 in ES cell proliferation and differentiation. We show that Suz12 is essential for proper differentiation, but not proliferation, of ES cells. Importantly, we show that different mechanisms of PcG transcriptional regulation exist during development. This involves active recruitment of PcGs to repress gene expression; however, we also demonstrate that increased levels of H3K27me3 and PcG binding can also correlate with the activation of gene expression.
|
|
|---|
ES cell karyotype and immunostaining. Growing ES cells were treated with Colticin (10 µl/ml; Gibco) for 1 h. Cells were harvested, incubated for 18 min in hypotonic solution (75 mM KCl), and subsequently fixed in fixative solution (1 volume of acetic acid in 3 volumes of methanol). Metaphases were allowed to dry on slides overnight at 37°C and were stained with DAPI (4',6'-diamidino-2-phenylindole; Sigma). For immunostaining, ES cells were cultured in normal ES cell medium on mitotically inactivated mouse embryonic fibroblasts (MEFs). Cells were fixed for 10 min in 4% buffered formaldehyde and stained with the antibodies indicated in the figure legends in the presence of 10% serum for 1 h in a humid chamber.
Antibodies. Immunoblotting and immunostaining were performed with the following antibodies: rabbit anti-Suz12, anti-H3K27me3, anti-H3K27me1 (where me1 indicates monomethylation), anti-H3K9me3, anti-H3K9me2, and anti-H3K4me2 from Upstate; rabbit anti ß-tubulin from Santa Cruz; rabbit anti-H3K27me2 (33); mouse anti-EZH2 BD43 (32); mouse anti-H3K27me2/me3 (31); and rabbit anti-Nanog and rabbit anti-Oct4 from Abcam. Chromatin immunoprecipitation (ChIP) analysis was performed with the following antibodies: rabbit anti-Suz12 and anti-H3K27me3 from Upstate, rabbit anti-polymerase II and rabbit antihemagglutinin (Y11) from Santa Cruz, mouse monoclonal antibody to EZH2 (AC22) (32), mouse monoclonal antibody to BMI1 (AF27) (5), and two rabbit affinity-purified polyclonal antibodies to CBX8 (hPc3), LAST and GALD (5).
Gene expression analysis. Total RNA was extracted independently from three Suz12+/ (clones SBE 4, SBE5, and SBE6) and three Suz12/ (clones SBE1, SBE7, and SBE8) ES cell clones. RNA was quantified, and equal amounts from the three Suz12+/ and the three Suz12/ samples were pooled into one sample to reduce the experimental variation. Targets for microarray hybridization were synthesized according to the supplier's instructions (Affymetrix). Hybridization, washing, staining, scanning, and data analysis were performed at the Affymetrix microarray unit at the Institute of Molecular Oncology of the Italian Foundation for Cancer Research-European Institute of Oncology campus, Milan, Italy, according to the manufacturer's instructions. Expression levels were analyzed using Microarray Analysis Suite, version 5.0, statistical algorithm software (Affymetrix), using the default parameters and scaling (TGT value) signal intensities for all the GeneChip arrays to a value of 500. The Suz12+/ samples were used as a baseline condition for comparison with the Suz12/ samples.
Quantitative PCR and primers. cDNA preparation and real-time quantitative PCR (qPCR) were performed following the manufacturer's instructions (Applied Biosystems). The analysis of the results was performed as described previously (32). For primer sequences see Table S2 in the supplemental material.
EB formation and neuronal differentiation. Embryoid bodies (EBs) were allowed to form in the absence of LIF in hanging drops containing 1,000 ES cells/20-µl drop on petri dish lids for 48 h. EBs were collected from the drops after 2 days and left in culture in noncoated petri dishes for the times indicated in the figure legends in ES medium in the absence of LIF. Medium was changed every 2 days. Neuronal differentiation followed the above EB formation protocol with the following modifications: EBs were treated from day 2 to day 5 with 0.5 µM all-trans-retinoic acid (ATRA) and plated on gelatin-coated dishes at day 7 to allow neuronal differentiation. For ChIP analysis EBs were formed as mass cultures by plating ES cells in suspension on noncoated petri dishes at the concentration of 5 x 105 cells/ml.
ChIP. ChIP assays were performed as described previously (6).
Animal studies. Animal care and experiments on live animals were performed at the University of Copenhagen in accordance with the Danish institutional and national guidelines (law number 726, 9 September 1993), and the studies were approved by the Dyreforsøgstilsynet committee (project number 2004/561-860).
|
|
|---|
![]() View larger version (31K): [in a new window] |
FIG. 1. Analysis of Suz12/ ES cells. (A) Phase-contrast pictures of growing Suz12+/ (clone SBE4) and Suz12/ (SBE8 8) ES cell clones growing on feeders cells. (B) Phase-contrast pictures (top) of growing Suz12+/ (clone SBE4) and Suz12/ (SBE1 and SBE8) ES cell clones on gelatin-coated plates. Genotype and sex determination PCRs (middle) show that both male (M) and female (F) Suz12/ ES cells can be derived. Immunoblots (bottom) using antibodies to Suz12, Ezh2, and ß-tubulin are shown. ß-Tubulin served as a loading control. KO, knockout; WT, wild type. (C) RNA expression levels of the ES cell markers Oct4 and Nanog in Suz12+/ and Suz12/ ES clones compared to MEFs. (D) Metaphase spreads showing a normal karyotype for Suz12+/ and Suz12/ ES clones. At the top the average numbers of counted chromosomes per cell are given. The bottom panels are representative pictures of metaphase spreads from Suz12+/ and Suz12/ ES clones. (E) Immunoblots of different histone H3 lysine (K) modifications using specific antibodies to the indicated proteins and their modifications.
|
![]() View larger version (48K): [in a new window] |
FIG. 2. Expression of Nanog and Oct4 in Suz12/ ES cells. Immunostaining of Suz12+/ and Suz12/ ES cells growing on feeders cells shown with anti-Nanog-specific (A) and anti-Oct4-specific (B) antibodies reveals expression of both ES cell markers in Suz12+/ and Suz12/ ES cells but not in feeder cells (arrows).
|
Suz12/ ES cells express higher levels of differentiation-specific genes. To further analyze the features of Suz12/ ES cells, we compared the global gene expression profiles of Suz12/ and Suz12+/ ES cells using Affymetrix oligonucleotide microarrays containing probes for more than 39,000 different mouse transcripts. Significantly, Suz12/ ES cells contain increased levels of differentiation-specific genes, suggesting that Suz12/ ES cells have differentiated features, despite displaying a normal stem cell phenotype (Fig. 3A). To validate the gene expression data, we determined the expression levels for 25 upregulated and 5 downregulated genes in Suz12/ and Suz12+/ ES cells by real-time qPCR. As shown in Fig. S1A in the supplemental material, the microarray data were confirmed for all the tested genes, demonstrating the high accuracy of the expression profile data. Because these genes could be potential direct targets of the PRC2 complex, we tested Ezh2 and Suz12 binding and the presence of H3K27me3 modification within a 3-kb promoter region upstream of the transcription start site of the genes. ChIP analysis revealed that 10% (3/30) of the analyzed genes were direct targets of PRC2 (see Fig. S1 in the supplemental material) and that Ezh2 binding and accumulation of H3K27me3 at the Tbx3, Satb2, and Otx2 promoters are dependent on Suz12 (see Fig. S1 in the supplemental material). These results are consistent with the requirement of Suz12 for Ezh2 enzymatic activity.
![]() View larger version (27K): [in a new window] |
FIG. 3. Suz12 is required for the regulation of a large number of genes involved in development, differentiation, and homeostasis. (A) Functional clustering of gene expression changes between Suz12+/ and Suz12/ ES cells. Expression downregulation refers to the functional clustering of genes whose expression was downregulated in Suz12/ compared to Suz12+/ ES cells. Expression upregulation refers to the functional clustering of genes whose expression was upregulated in Suz12/ compared to Suz12+/ ES cells. (B) Expression (top) and ChIP analysis using the indicated antibodies (bottom) were determined by real-time qPCR. HA, hemagglutinin. (C) Expression levels of H19 in Suz12+/ and Suz12/ male ES clones.
|
Interestingly, we also found that the expression of the paternally imprinted H19 gene is significantly increased in Suz12/ ES cells relative to expression in to Suz12+/ ES cells (Fig. 3C; see also Table S1 and Fig. S1A in the supplemental material). This result is consistent with the requirement of Eed for the imprinting of different autosomal loci (24), suggesting that imprinting could also be affected in Suz12/ embryos. To understand if the PRC2 complex and H3K27me3 are directly involved in the maintenance of H19 repression, we analyzed the binding of Ezh2 and Suz12 and the presence of histone H3K27me3 modification both at the H19 promoter (5 to +1 kb with respect to the transcription start site) and at the CG regulatory element placed at the 3' end of the H19 locus. ChIP analysis showed that neither PRC2 nor H3K27me3 was present in the analyzed genomic regions (see Fig. S1A in the supplemental material), suggesting that either the PRC2 regulation is indirect or that it involves the recruitment of PRC2 activity at different sites or in earlier developmental stages.
Suz12 is required for differentiation of ES cells. Our findings are consistent with the fact that Suz12/, Ezh2/, and Eed/ embryos are all able to implant but fail to undergo further development, and they suggest that PRC2 and its enzymatic activity are required for the differentiation processes taking place during development. To investigate this, we took advantage of the fact that ES cells undergo neuronal differentiation in the presence of ATRA. Thus, we treated Suz12+/ and Suz12/ ES cells with ATRA and found that while Suz12+/ ES cells efficiently form neurons, we were unable to detect any neurons in ATRA-treated Suz12/ ES cells (Fig. 4A; see also Fig. S2A in the supplemental material). Consistent with this, the expression of two neuron-specific markers, GluR6 and Gad65, was strongly activated in Suz12+/ differentiated cells, but not in Suz12/ cells (Fig. 4B; see also Fig. S2B in the supplemental material).
![]() View larger version (81K): [in a new window] |
FIG. 4. Suz12/ ES cells fail to undergo proper differentiation. (A) Phase-contrast pictures of neuronal differentiation of Suz12+/ and Suz12/ ES cells. Arrows in the left panels show neuron formation in Suz12+/ cells, while the right panels show lack of neuron formation in Suz12/ cells. (B) Expression levels of two specific neuronal markers GluR6 and Gad65 showing strong activation in differentiated Suz12+/ cells and no activation in Suz12/ cells. Undiff, undifferentiated; diff, differentiated. (C) Hematoxylin and eosin staining of 7-day EBs formed by Suz12+/ and Suz12/ ES cells. Top panels show normal morphology of Suz12+/ EBs. High-magnification fields highlight outer endodermal layers and epithelium-like cavities. Bottom panels show Suz12/ EBs that lack forms of organized structures and that are often smaller.
|
To further support these results, we compared the expression of specific ES cell markers as well as the expression of genes specifically activated during gastrulation in Suz12+/ and Suz12/ differentiating ES cells. Consistent with the lack of germ layer formation, the expression of gastrulation-specific genes (Brachyury, Pax3, Pax7, Fgf3, and Wnt3a) was activated only in Suz12+/ and not Suz12/ EBs (Fig. 5B). Moreover, the expression of Oct4 and Nanog was fully repressed during ES cell differentiation in Suz12+/ ES cells, whereas the expression of the two stem cell transcription factors was only partly repressed in Suz12/ EBs (Fig. 5A; see Fig. S2D in the supplemental material), with expression levels approximately 50-fold higher in Suz12/ EBs at 9 days of differentiation (Fig. 5A, right). Western blots presented in Fig. 5C further confirm this result and show that Oct4 and Nanog protein levels are indeed still expressed in Suz12/ differentiated ES cells but not in the control cells. Similar expression results were also obtained for other genes like Fgf4, Fgf17, and Pou2F3 that are expressed in ES cells and repressed upon differentiation (Fig. 4A).
![]() View larger version (28K): [in a new window] |
FIG. 5. Suz12/ ES cells fail to repress ES cells markers and to activate differentiation-specific genes upon induction of differentiation. (A) Expression levels of Oct4, Nanog, Fgf4, Fgf17, and Pou2f3 in ES cells and in 9-day differentiated EBs determined by real-time qPCR. Right panels highlight the expression differences between Suz12+/ and Suz12/ in 9-day differentiated EBs. (B) Expression levels of gastrulation markers in ES cells and in EBs at 3, 6, and 9 days after induction of differentiation. (C) Immunoblotting for Oct4 and Nanog during Suz12+/ and Suz12/ ES cell differentiation showing repression of Oct4 and Nanog expression in Suz12+/ but not Suz12/ ES cells. (D) Expression levels of Sox1, Nestin, Mausashi, and Calib2 during Suz12+/ and Suz12/ ES cell differentiation showing the lack of activation of the neuronal precursor marker in Suz12/ cells.
|
Mechanisms for PRC-mediated transcriptional regulation during differentiation. Recently, we have identified genes targeted by PRC2 and PRC1 in a human diploid fibroblast cell line, TIG3 (5). Interestingly, the genes presented in Fig. 5A and B were identified as direct targets of both PRCs in TIG3 cells, suggesting that the PRCs remain associated with the promoters after their recruitment during early embryogenesis. To determine if the binding of the PRCs is conserved between human and mouse, we performed ChIP analysis in MEFs (see Fig. S3A and B in the supplemental material). While Ezh2, Suz12, and histone H3K27me3 were present on all promoters, the PRC1 proteins Cbx8 and Bmi1 were not. Significant Cbx8 binding was detected at the Brachyury, Pax3, Pax7, Fgf4, and Oct4 promoters, while significant Bmi1 binding was detected at all promoters except for the Pou2f3. The differential binding could be due to cell type differences and suggests that the composition of PRC1 may differ from one cell type to another. However, the results show that PRC2 binding at these genes is fully conserved between mouse and human.
Interestingly, while Brachyury, Pax3, Pax7, Wnt3A, and Fgf3 are expressed at low levels in ES cells and become activated upon differentiation (Fig. 4 and 5B), Fgf4, Pou2F3, Fgf17, Nanog, and Oct4 are expressed in ES cells and become repressed upon differentiation (Fig. 5A). Nanog and Oct4 are essential transcription factors for ES cell self-renewal (17, 25) and function both as activators and repressors of important developmental regulators (3, 23). Pou2f3 is a member of the Oct transcription factor family, but its biological role is poorly characterized. Instead, Fgf4 and Fgf17 function as signaling molecules that play a crucial role in the control of development. Fgf4, for example, is required for the proliferation of trophoblast stem cells (14).
To start addressing the mechanisms regulating the expression of the PcG target genes during early differentiation, we analyzed the recruitment of Ezh2, Suz12, and H3K27me3 in both Suz12+/ and Suz12/ ES cells induced to undergo differentiation. Surprisingly, we found that even though these two groups of genes are inversely expressed during ES cell differentiation (Fig. 5A and B), increased amounts of H3K27me3 associate with all the promoters in a Suz12-dependent manner during ES cell differentiation (Fig. 6 and 7A). In fact, consistent with the requirement of Suz12 for Ezh2 histone methyl transferase activity, Ezh2 binding and H3K27me3 association were abolished in Suz12/ differentiated ES cells (Fig. 6 and 7A). This result demonstrates that increased association of histone H3K27me3 does not prevent transcription and indicates that this modification could have a role in transcriptional activation. Despite the binding of PRC2 to the Oct4 and Nanog promoters in MEFs (see Fig. S3 in the supplemental material), we were unable to detect any significant PRC2 binding and H3K27me3 association to these promoters during ES cell differentiation (see Fig. S4 in the supplemental material), suggesting that PRC2 indirectly regulates these promoters during the early events of ES cell differentiation.
![]() View larger version (27K): [in a new window] |
FIG. 6. PcG binding does not prevent transcriptional activation. ChIP analyses performed on promoters of genes that are activated during differentiation of ES cells. Real-time qPCR was used to determine the expression levels of the genes, and values were normalized as described in Materials and Methods. Antibodies specific for Ezh2, Suz12, Cbx8, Bmi1, H3K27me3, and the hemagglutinin (HA) epitope (negative control) were used for ChIPs. Enrichment is given as a percentage of input. Black bars, Suz12+/ cells; red bars, Suz12/ cells; d, day; Ab, antibody.
|
![]() View larger version (34K): [in a new window] |
FIG. 7. PRC2 is actively recruited to repress gene transcription during ES cell differentiation. (A) ChIP analysis of the promoter regions of repressed genes during ES cell differentiation using antibodies against Ezh2, Suz12, Cbx8, Bmi1, and histone H3K27me3. Results of ChIPs and qPRCs in Suz12+/ (black bars) and Suz12/ ES cells (red bars) are shown. The expression profile for each gene during differentiation is also presented (far left). HA, hemagglutinin; Ab, antibody. (B) Immunoblots of Suz12, Ezh2, Eed, Cbx8, and Bmi1 in Suz12+/ and Suz12/ ES cells and in proliferating (P3) and senescent (P7) MEFs. ß-Tubulin served as a loading control. (C) Different models for how the PcG proteins regulate transcription during differentiation. In the derepression model (1) the PcGs repress the expression of differentiation-specific genes in proliferating ES cells. The loss of PcG binding during differentiation leads to the activation or derepression of transcription. In the repression model (2) the PcGs are specifically recruited to target genes that undergo transcriptional repression during differentiation. In the activation model (3) PcGs (PRC2) accumulate on a subset of target genes during differentiation despite their transcriptional activation. In this model we propose that the binding of transcriptional activators is sufficient to overcome the PcGs. The binding of the PcGs could be important for the repression of the target genes during terminal differentiation and in this way preprogram the target genes during early development.
|
Interestingly, Cbx8 and Bmi1 are not present on PcG target genes in nondifferentiated ES cells (Fig. 6 and 7A and data not shown). To obtain a potential explanation for this, we prepared cell lysates from Suz12+/ and Suz12/ ES cells at different stages of differentiation, and from proliferating (passage 3 [P3]) and senescent (P7) MEFs (Fig. 5B). Remarkably, Cbx8 is not detectably expressed in undifferentiated ES cells but accumulates during differentiation (Fig. 7B). Interestingly, Cbx8 expression is not fully induced in Suz12/ differentiated ES cells, which could be a result of the lack of proper differentiation of these cells. Unlike Cbx8, Bmi1 is expressed in ES cells and further accumulates 3 days after induction of differentiation. However, since Bmi1 is not recruited to PRC1 target genes in nondifferentiated cells, this may suggest that Bmi1 recruitment is dependent on Cbx8 expression. In addition, slower-migrating forms, which might result from phosphorylations, as suggested by previously published findings, (35), appear during the differentiation of the ES cells with kinetics similar to Cbx8 accumulation. These forms become prominent in MEFs, which may suggest that posttranslation modifications of Bmi1 could be a regulatory mechanism for the recruitment of PRC1 to target genes.
|
|
|---|
In this work we have shown that even though Suz12/ ES cells proliferate and appear normal, their ability to undergo proper differentiation is compromised. We provide evidence that this is due to the failure to establish the correct transcription programs during early embryogenesis. This assumption is in agreement both with the fact that Suz12/ and Eed mutant ES cells expression patterns are altered toward a more differentiated phenotype and with the finding that Ezh2 activity is required for correct development before the four-cell stage during embryogenesis (4, 13). Similarly to Suz12/ ES cells, Eed mutant ES cells can be maintained in culture, and, despite their tendency to differentiate (4), they can efficiently form EBs in vitro and contribute to gastrulation in vivo in chimeric embryos (27). Interestingly, the fact that Ezh2 (30), but not Eed and Suz12, is required for ES cell proliferation indicates that Ezh2 has additional functions independent of H3K27 methylation. This notion is supported by data obtained in Drosophila, where mutants of the Ezh2 homologue E(z) have additional phenotypic defects to those observed in Esc (dEed) and Su(z)12 (dSuz12) mutant flies (1, 20, 34).
The effects of the lack of PRC2 transcriptional control are more evident when Suz12/ ES cells are induced to differentiate. We found that Suz12 is required for proper ES cell differentiation. Key developmental transcription factors such as Brachyury, Pax3, and Pax7 as well as early neuronal markers such as Sox1, Nestin, Musashi, and Calb2 are not activated by differentiation signals in the absence of Suz12. Moreover, during differentiation Suz12 appears to be required for the repression of genes essential for ES cell self-renewal, such as Nanog and Oct4. This could be a consequence of the differentiation failure of the Suz12/ ES cells, but since ectopic expression of Nanog can block ES cell differentiation in vitro (11), sustained Nanog expression in the Suz12/ ES cells could also contribute to the impairment of proper differentiation of the Suz12/ ES cells. Our results showing that PcGs bind directly to the Nanog and Oct4 promoters in MEFs and that they are associated with H3K27me3 support the notion that the expression of these promoters is controlled by the PcGs. In any event, it would be extremely interesting to know if the differentiation defects of Suz12/ ES cells depend on lack of Nanog and/or Oct4 repression; however, this experiment is unfortunately not feasible because ES cells do not grow in the absence of the two transcription factors (25, 29).
Our results demonstrating the accumulation of the PRCs and H3K27me3 on promoters for differentiation-induced genes is very exciting and support our previous findings that PcG-binding and H3K27me3 accumulation might not be sufficient to prevent transcription (5). In our previous work (5), we proposed that PcG binding to active promoters in progenitor cells preprograms these genes for repression during terminal differentiation. Here, we have provided evidence that the PcGs are indeed specifically recruited to active promoters in progenitor cells. Moreover, our results could further suggest that the recruitment of the PcGs to these target genes may be required for their transcriptional activation.
In addition to demonstrating the essential role of Suz12 in ES cell differentiation, our analysis of PcG target genes suggests a number of mechanisms by which the PcGs control transcription. So far the only mechanism that is backed up by experimental data is outlined in the derepression model (Fig. 7C, model 1). This model involves the dissociation of PcG proteins upon induction of differentiation and allows activation of target genes and subsequent differentiation. Several experimental results using myoblasts (10), ES cells (4, 21), and NTera2 cells (5) support this model. ChIP analysis presented in this work further supports the derepression model showing that differentiation-specific genes are indeed repressed by the PcGs in Suz12+/ ES cells and that this repressive activity is lost in Suz12/ ES cells.
In this study, we have shown that the PcGs are also actively recruited to target genes upon induction of differentiation. Surprisingly, we found that this recruitment can correlate with either transcriptional repression or activation of genes during differentiation.
In the first case, we found that differentiation signals lead to recruitment of PRC2 to target genes and that this recruitment correlates with repression of transcription. Importantly, this repression is dependent on Suz12, suggesting that direct binding of PRC2 plays a critical role in the repression of these genes. Based on these results we propose a mechanism, summarized in the repression model presented in Fig. 7C, whereby the PcGs regulate transcription of specific target genes during differentiation. If this model is accurate, the identification of the signaling pathways and the factors that trigger the specific recruitment of the PRCs will be important for understanding how differentiation is regulated.
In the second case, we found increased levels of PRC2 on the promoters of genes activated during differentiation. Since PRC2 is believed to function as a repressor of transcription, this is an intriguing result. Furthermore, the striking observation that the genes were not activated in Suz12/ ES cells, i.e., in the absence of PRC2 recruitment, could suggest that PRC2 has a direct role in the transcriptional activation of these targets. However, it is important to stress that the lack of transcriptional activation could be a consequence of the failure of Suz12/ ES cells to undergo proper differentiation. In this case, the early recruitment of the PRCs could simply epigenetically predispose these genes for later repression. A model for how PcGs may participate in the activation of target genes is depicted in Fig. 7C.
In conclusion, our results and those from other laboratories demonstrate that Suz12 and PRC2 are required for ES cell differentiation, most likely by directly controlling specific gene expression during cellular commitment. ES cells become an attractive tool for regenerative therapy due to their in vitro differentiation potential. Embryo cloning by somatic cell nuclear transfer (SCNT) could give important therapeutic advantages as a source of ES-like cells that can be in vitro differentiated and used for autologous implants. Low efficiency in therapeutic cloning is the major obstacle to overcome because epigenetic commitment of somatic cells is a major problem in successful embryo cloning. The failure to achieve correct reactivation of genes like Nanog and Oct4 has been linked to the failure of embryos obtained by SCNT to implant and successfully develop. Manipulation of PRC2 activity could therefore contribute to the reprogramming of somatic cells and increase the efficiency of successful SCNT embryo cloning.
This work was supported by grants from the Association for International Cancer Research, the Danish Cancer Society, the Danish Medical Research Council, the Danish Natural Science Research Council, and the Danish National Research Foundation. J.B.H. was supported by grants from the Carlsberg Foundation and the Novo Nordisk Foundation.
Published ahead of print on 5 March 2007. ![]()
Supplemental material for this article may be found at http://mcb.asm.org/. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»